This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, J. A. Articles by Ostrand-Rosenberg, S. Search for Related Content PubMed PubMed Citation Articles by Thompson, J. A. Articles by Ostrand-Rosenberg, S.

Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4⁺ T Cells Whether or Not They Are Silenced for Invariant Chain

¹ Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland; ² The Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; and ³ Division of Oncology, University of Washington, Seattle, Washington

Requests for reprints: Suzanne Ostrand-Rosenberg, Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250. Phone: 410-455-2237; Fax: 410-455-3875; E-mail: srosenbe{at}umbc.edu.

The specificity and potency of the immune system make immunotherapy a potential strategy for the treatment of cancer. To exploit this potential, we have developed cell-based cancer vaccines consisting of tumor cells expressing syngeneic MHC class II and costimulatory molecules. The vaccines mediate tumor regression in mice and activate human CD4⁺ T cells in vitro. Previous vaccines were generated by transducing MHC II negative tumor cells with a single HLA-DR allele. Because expression of multiple MHC II alleles would facilitate presentation of a broader repertoire of tumor antigens, we have now transduced tumor cells with the MHC class II transactivator (CIITA), a regulatory gene that coordinately increases expression of all MHC II alleles. Previous studies in mice indicated that coexpression of the MHC II accessory molecule invariant chain (Ii) inhibited presentation of endogenously synthesized tumor antigens and reduced vaccine efficacy. To determine if Ii expression affects presentation of MHC class II–restricted endogenously synthesized tumor antigens in human tumor cells, HLA-DR-MCF10 breast cancer cells were transduced with the CIITA, CD80 costimulatory molecule gene, and with or without small interfering RNAs (siRNA) specific for Ii. Ii expression is silenced >95% in CIITA/CD80/siRNA transductants; down-regulation of Ii does not affect HLA-DR expression or stability; and Ii⁺ and Ii^– transductants activate human CD4⁺ T cells to DRB1*0701-restricted HER-2/neu epitopes. Therefore, tumor cells transduced with the CIITA, CD80, and with or without Ii siRNA present endogenously synthesized tumor antigens and are potential vaccines for activating tumor-specific CD4⁺ T cells. (Cancer Res 2006; 66(2): 1147-54)

This article has been cited by other articles:

				D. Kim, T. Hoory, A. Monie, J. P.-Y. Ting, C.-F. Hung, and T.-C. Wu Enhancement of DNA Vaccine Potency through Coadministration of CIITA DNA with DNA Vaccines via Gene Gun J. Immunol., May 15, 2008; 180(10): 7019 - 7027. [Abstract] [Full Text] [PDF]

				E. C. de Bruin, C. J.H. van de Velde, J. H. J.M. van Krieken, C. A.M. Marijnen, and J. P. Medema Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients Clin. Cancer Res., February 15, 2008; 14(4): 1073 - 1079. [Abstract] [Full Text] [PDF]

				J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells Cancer Res., May 1, 2007; 67(9): 4499 - 4506. [Abstract] [Full Text] [PDF]

				S. A. Oldford, J. D. Robb, D. Codner, V. Gadag, P. H. Watson, and S. Drover Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients Int. Immunol., November 1, 2006; 18(11): 1591 - 1602. [Abstract] [Full Text] [PDF]